The constitutive negative charge within the BRAF NtA region leaves the protein ‘primed’ for dimerisation, and able to be activated by single site phosphorylation or single point mutations [64]; this may explain why BRAF mutations are far more common in cancer than ARAF or CRAF mutations. The gene discussed is BRAF; the disease is cancer.